Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory disease with a high mortality of ~ 35%. The lack of approved treatments for MERS-CoV infection underscores the need for a user-friendly system for rapid drug screening. In this study, we constructed a MERS-CoV replicon containing the Renilla luciferase (Rluc) reporter gene and a stable luciferase replicon-carrying cell line. Using this cell line, we showed that MERS-CoV replication was inhibited by combined application of lopinavir and ritonavir, indicating that this cell line can be used to screen inhibitors of MERS-CoV replication. Importantly, the MERS-replicon cell line can be used for high-throughput screening of antiviral drugs without the need for live virus handling, providing an effective and safe tool for the discovery of antiviral drugs against MERS-CoV.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898024 | PMC |
| http://dx.doi.org/10.1007/s12250-020-00341-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Conserved role of spike S2 domain N-glycosylation across beta-coronavirus family.
bioRxiv
September 2024
Chemical & Biological Engineering, State University of New York, Buffalo, NY 14260, USA.
Besides acting as an immunological shield, the N-glycans of SARS-CoV-2 are also critical for viral life cycle. As the S2 subunit of spike is highly conserved across beta-coronaviruses, we determined the functional significance of the five 'stem N-glycans' located in S2 between N1098-N1194. Studies were performed with 31 Asn-to-Gln mutants, beta-coronavirus virus-like particles and single-cycle viral replicons.
View Article and Find Full Text PDFSARS-CoV-2 papain-like protease inhibits ISGylation of the viral nucleocapsid protein to evade host anti-viral immunity.
J Virol
September 2024
Division of Infectious Disease Control, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan.
Article Synopsis
- SARS-CoV-2 causes a range of respiratory symptoms, and although research has made strides in understanding the virus, many aspects of its infection process are still not fully understood.
- The study focuses on the interferon-inducible protein ISG15, which is involved in suppressing viral functions through a process called ISGylation, and how SARS-CoV-2's protease, PLpro, interferes with this process.
- Results show that ISGylation of the SARS-CoV-2 nucleocapsid protein disrupts viral replication, indicating that the virus has evolved mechanisms to evade ISGylation to enhance its own replication efficiency.
Identification of a membrane-associated element (MAE) in the C-terminal region of SARS-CoV-2 nsp6 that is essential for viral replication.
J Virol
May 2024
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, and Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel coronavirus severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), has rapidly spread worldwide since its emergence in late 2019. Its ongoing evolution poses challenges for antiviral drug development. Coronavirus nsp6, a multiple-spanning transmembrane protein, participates in the biogenesis of the viral replication complex, which accommodates the viral replication-transcription complex.
View Article and Find Full Text PDFEvaluation of antiviral activity of SARS-CoV-2 M inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions.
Antimicrob Agents Chemother
November 2023
Pardes Biosciences, Inc. , Carlsbad, California, USA.
The unprecedented scale of the COVID-19 pandemic and the rapid evolution of SARS-CoV-2 variants underscore the need for broadly active inhibitors with a high barrier to resistance. The coronavirus main protease (M) is an essential cysteine protease required for viral polyprotein processing and is highly conserved across human coronaviruses. Pomotrelvir is a novel M inhibitor that has recently completed a phase 2 clinical trial.
View Article and Find Full Text PDFImmunization of MERS-CoV-2-infected mice with a sublethal dose of MERS-CoV or VRP-MERS-S.
STAR Protoc
February 2023
Departments of Microbiology and Immunology, University of Iowa, Iowa City, IA 52242, USA; Departments of Pediatrics, University of Iowa, Iowa City, IA 52242, USA. Electronic address:
Here, we detail the immunization of mice with a sublethal dose of MERS-CoV or two doses of replication-incompetent alphavirus replicon particles expressing MERS-CoV spike protein. We then describe steps to determine the outcome of immunization by challenging immunized mice with a lethal dose of MERS-CoV, as well as by detecting virus-specific neutralizing antibody and virus-specific T cell response via neutralization assay and flow cytometry, respectively. This protocol can be used to evaluate other CoV infections or vaccine-induced immune responses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!